AMLo Biosciences Limited

AMLo Biosciences Limited, based in the UK, specializes in developing innovative prognostic tests for skin cancers, focusing on melanoma, cutaneous squamous cell carcinoma, and oropharyngeal squamous cell carcinoma to improve patient care. AMLo Biosciences Limited, founded in 2017 in Newcastle upon Tyne, UK, focuses on creating diagnostic tools for skin cancers. The company has completed 4 funding deals, with the most recent occurring on November 7, 2024, where it raised GBP 1. 6 million from investors Esperante Ventures and Northstar Ventures.

The firm has been led by CEO Marie Labus since its inception, although there are no mentions of prior companies founded by her. AMLo Biosciences develops prognostic tests such as AMBLor®, which assesses disease progression risk in early-stage melanomas. The company provides these tests primarily to UK healthcare providers and plans to expand into markets in Australia, New Zealand, the United States, and Europe, where the demand for advanced diagnostic tools is prevalent. The company generates revenue through direct sales of its prognostic tests to healthcare providers, typically through B2B relationships.

While specific pricing details are not disclosed, the revenue model is based on one-time purchases or subscription agreements for ongoing diagnostic services, focusing on skin cancer treatment and management. Following the recent funding of GBP 1. 6 million, AMLo Biosciences plans to commercialize diagnostic kits across public and private healthcare sectors in the UK, expand operations into the US, and explore global market opportunities. The funding will support these initiatives, alongside the continued development of products aimed at enhancing patient outcomes.